PharmAust (ASX:PAA) share price soars 7% on positive update

The PharmAust Limited (ASX: PAA) share price is shooting upwards following an update on its antiviral program. Here is what the company said.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The PharmAust Limited (ASX: PAA) share price is shooting upwards following an update on its antiviral program. In late afternoon trade, the PharmAust share price is trading for 11 cents apiece, up 7.1%.

What did PharmAust announce?

Investors are pushing PharmAust shares higher after taking in the company's progress on antiviral activity against COVID-19.

In its announcement, PharmAust provided an update on its lead drug candidates as antiviral therapeutics. These include monepantel (MPL) and also monepantel sulfone (MPLS).

The company stated that data from extensive testing at Leiden University Medical Center (LUMC) has demonstrated antiviral activity in non-human primate systems. This follows two previous independent laboratories that conducted MPL's antiviral activity in both primate and non-primate cell cultures mid-last year.

MPL and its metabolite MPLS are potent and safe inhibitor of the mTOR pathway. This is the pathway that influences cancer growth, neurodegenerative diseases, and viral infections. MPL has been evaluated in the human phase 1 trial and exhibited preliminary evidence of anticancer activity.

PharmAust noted that solubility issues of MPL in the in-vitro systems remain challenging. However, it has resolved solubility issues of the administration to patients through developing an MPL tablet dosage form.

When consumed, MPL is converted to MPLS in the body, representing the dominant form in a person's plasma.

Principal investigator at LUMC, associate professor Martijn van Hemert commented:

There are indications for an antiviral effect in these assays, but solubility issues under the conditions required for cell-based screening complicate analysis. Additional experiments will now be performed on SARS-CoV-2 infected human lung cell lines

PharmAust Chief Scientific Officer, Dr Richard Mollard added:

Testing highly insoluble drugs such as MPL in established complex culture conditions is notoriously difficult. We look forward to updating the market as these programs continue.

PharmAust and LUMC will seek to move its antiviral development program to testing in human cells.

PharmAust share price snapshot

Over the past 12 months, the PharmAust share price has accelerated over 50% of its value. Most of the gains came from June 2020 when the company announced its preliminary COVID-19 results.

On valuation grounds, PharmAust presides a market capitalisation of around $33.2 million, with 316.7 million shares outstanding.

Should you invest $1,000 in Immutep Limited right now?

Before you buy Immutep Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Immutep Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors this Tuesday.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why HMC Capital, Platinum, Sigma, and Skycity shares are dropping today

These shares are having a tough session on Tuesday. But why?

Read more »

A close-up photo of a ballot box with an Australian flag in front of it and a gentleman's hands placing his vote in the 2022 election inside the box
Share Market News

How these ASX 200 stocks are primed to gain from Labor's resounding Federal election win

With the Federal election in the rear-view, which ASX 200 stocks should I buy now?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

These shares are rising when many are falling today. But why?

Read more »

Smiling young woman eating chocolate outdoors.
Share Market News

The See's Candies playbook for ASX investors

Two ASX businesses that remind me of Buffett’s sweetest investment.

Read more »

Man smiling at a laptop because of a rising share price.
Opinions

My 2 favourite ASX sectors to invest in

Finding your groove can help your investing success.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Opinions

3 things I learned from Warren Buffett being the CEO of Berkshire Hathaway

The Oracle from Omaha is in his last year as CEO.

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the local market today.

Read more »